Lifileucel Approval Paves the Way for Personalized Minimally-Invasive T-Cell Therapies
February 25th 2025The FDA’s accelerated approval of lifileucel (Amtagvi; Iovance Biotherapeutics) marks a major milestone in immunotherapy for metastatic melanoma, building on decades of research in tumor-infiltrating lymphocyte therapy.
Read More
James P. Allison and the Discovery of CTLA-4: How Immune Checkpoint Blockade Revolutionized Oncology
February 25th 2025Immunotherapy pioneer James P. Allison, PhD, revolutionized cancer treatment by discovering immune checkpoint blockade, leading to significant advances in survival rates and ongoing efforts to optimize immuno-oncology strategies.
Read More
Emerging Role of BRAF Inhibitors in Relapsed/Refractory Hairy Cell Leukemia Treatment
BRAF V600E inhibitors show improved outcomes in relapsed/refractory hairy cell leukemia.
Read More
Key Considerations for Pharmacists in Hemophilia B Treatment With Etranacogene Dezaparvovec
February 24th 2025Etranacogene dezaparvovec offers a long-term, cost-effective solution for hemophilia B by providing sustained factor IX expression but requires careful patient selection and post-infusion liver monitoring.
Watch
Key Sessions and Opportunities for Pharmacists at the AACR Immunotherapy Conference
February 21st 2025The AACR Immunotherapy Conference 2025 will provide pharmacists with the opportunity to engage with cutting-edge cancer immunotherapy research, explore advancements in treatments, such as immune checkpoint inhibitors and CAR T-cell therapy, and connect with key leaders in the field.
Read More
Intestinal Microbiome May Play a Role in CAR T-Cell Therapy Outcomes
February 21st 2025Melody Smith, MD, MS, discusses how the intestinal microbiome influences CAR T-cell therapy outcomes, highlighting the negative impact of certain antibiotics and the potential role of dietary interventions in improving treatment efficacy.
Watch